Uliledlimab
TJ004309First anti-CD73 to reach Phase 3 — TJ Biopharma's NSCLC trial. Western competitors (oleclumab/AZ, quemliclustat/Arcus) are still in Phase 2.
Target: NT5E monoclonal antibody (anti-CD73) TJ Biopharma Co., Ltd. Oncology
When will we know if it works?
Fresh est.A positive readout makes NT5E a validated target for the first time. Hover the badge above for what the confidence level means.
1
Phase 3 trials
1 active · 0 completed
2
Total trials
P2: 1 · P1: 0
450
Max trial size
across 1 indications
1
Sponsors at target
incl. 3 other assets
What does it do?
NT5E — Ecto-5'-nucleotidase (CD73)
Modality: monoclonal antibody (anti-CD73)
The 1 Phase 3 trial
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT06984588 | Non Small Cell Lung Cancer | 450 | ACTIVE_NOT_RECRUITING | 2024-03-28 | 2028-08-05 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2018 | origin | I-Mab Biopharma (originator before transfer to TJ Biopharma) | In-house |
What's the case for and against?
✓ What's working in its favor
- Phase 2 NSCLC + checkpoint inhibitor: ~63% disease control rate
Who else is racing? — 3 other assets at NT5E
| Asset | Sponsor | Status |
|---|---|---|
| Oleclumab (MEDI9447) | AstraZeneca | P2 NEPTUNE NSCLC |
| Quemliclustat (AB680) | Arcus Biosciences | P1/P2 |
| Mupadolimab | Corvus Pharmaceuticals | P1/P2 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.